Glenmark Pharmaceuticals

    GLENMARK
    Pharma
    ₹2419.20
    price as of 11/9/2026, 5:28:13 pm

    Market cap ₹68,276 Cr

    P/E
    37.94
    Day range
    ₹2,384.10 – ₹2,431.90
    52-week range
    ₹1,792.60 – ₹2,537.60
    Volume
    3.47 L
    Open
    ₹2,411.20
    Prev close
    ₹2,415.00
    Promoters pledged 2.7% of their shares
    52-week range, adjusted for splits and bonuses
    ₹1,792.6₹2,537.6
    28 Oct 202528 Aug 2026
    Index membership & F&O
    NIFTY 200NIFTY 500NIFTY MIDCAP 150NIFTY HEALTHCARENIFTY PHARMAF&O lot 375

    Price history

    6M change +6.45%RSI (14) 54.9 NeutralSMA 20 · 50 overlaid

    Price & delivery on the exchange

    NSE bhavcopy to 11 Sept 2026 · delivery 55.3% today vs 46.0% average · BSE close ₹2,416.9

    1 Apr23 Apr15 May5 Jun24 Jun15 Jul3 Aug21 Aug11 Sept₹1,950₹2,100₹2,250₹2,400₹2,5500%25%50%75%100%
    • Delivery
    • NSE close
    • BSE close

    High delivery with a rising price suggests buyers holding rather than trading the move.

    Futures & options

    NSE F&O close, 11 Sept 2026 · options expiring 29 Sept 2026

    Neutral
    Near-month future
    ₹2,423.5
    Change
    +0.00%
    Basis over spot
    +₹4.31
    Futures OI (shares)
    1.14 Cr
    OI change
    +0.36%
    Put-call ratio
    0.51
    Max pain
    ₹2,400
    Resistance (call OI)
    ₹2,500
    Support (put OI)
    ₹2,400
    Lot size
    375

    Open interest by strike

    Calls open above (resistance) and puts below (support), in shares

    208021402200226023202380244025002560262026802740284001.0 L2.0 L3.0 L4.0 Lspot
    • Call OI
    • Put OI

    Futures open interest and price

    Near-month future, day by day since collection began

    The daily history builds from each close.

    Key metrics

    P/E (TTM)
    34.6
    EPS (TTM)
    ₹63.68
    Price / Book
    6.54
    ROE (FY26)
    14.1%
    ROCE (latest year)
    40%
    Dividend yield
    0.21%
    Net margin (TTM)
    10.1%
    Current ratio
    1.77
    Debt / Equity
    0.05
    Revenue growth (5y)
    9.2%
    EPS growth (5y)
    7.0%

    Moving averages (NSE)

    Simple moving averages of the NSE price, and where the last price sits against each
    5-day10-day20-day50-day100-day300-day
    ₹2,460.22Price below₹2,459.44Price below₹2,386.04Price above₹2,297.79Price above₹2,283.42Price above₹2,154.27Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +13.6%
    Profit 3Y CAGR
    +53.4%
    Revenue YoY (Jun 2026)
    +23.1%
    Profit YoY (Jun 2026)
    +927.7%
    Operating margin
    20.0%
    Net margin
    12.0%

    Revenue, profit & margin - quarterly

    Bars in ₹ crore (a loss shows red); line is operating margin

    Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Jun 2026-2.5K Cr0 Cr2.5K Cr5.0K Cr7.5K Cr-15%0%15%30%45%
    • Revenue
    • Net profit
    • Operating margin

    Who owns the company

    Shareholding as of Jun 2026

    • Promoter
    • FII
    • DII
    • Public
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-5.0K Cr-2.5K Cr0 Cr2.5K Cr5.0K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26-30%-15%0%15%30%15%

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); line is debt-to-equity

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 20260 Cr3.0K Cr6.0K Cr9.0K Cr12.0K Cr0.0x0.3x0.6x0.9x1.2x
    • Equity
    • Debt
    • Debt / equity

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    Sales3,2072,5073,0633,2443,4343,3883,2563,2646,0473,9013,7714,018
    Expenses2,7452,7152,5592,6562,8322,7872,6952,6843,6873,0313,0083,214
    Operating Profit462-2095045886026005615812,360870763805
    OPM %14%-8%16%18%18%18%17%18%39%22%20%20%
    Other Income-20587351313931-361-297-1,184-140-18466
    Interest121134149404852675866414354
    Depreciation141147151118120123125130141154148173
    Profit before tax-6-403555462473456896967534388643
    Tax %997%-18%319%26%25%24%45%51%37%24%22%25%
    Net Profit-62-331-1,214340354348447610403301483
    EPS in Rs₹-2.90₹-12.45₹-43.17₹12.06₹12.55₹12.33₹0.16₹1.66₹21.63₹14.29₹10.68₹17.11

    From company filings, updated 11 Sept 2026. Consolidated figures where the company reports them.Information only, not investment advice.

    Strengths, risks & growth

    Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. [1]

    Strengths

    • Company has reduced debt.
    • Company is almost debt free.
    • Company has delivered good profit growth of 19.4% CAGR over last 5 years

    Risks

    • The company has delivered a poor sales growth of 9.19% over past five years.
    • Company has a low return on equity of -3.28% over last 3 years.
    • Debtor days have increased from 85.2 to 107 days.
    • Working capital days have increased from 41.2 days to 80.5 days

    Compounded Sales Growth

    10 Years
    +8%
    5 Years
    +9%
    3 Years
    +14%
    TTM
    +33%

    Compounded Profit Growth

    10 Years
    +12%
    5 Years
    +19%
    3 Years
    +61%
    TTM
    +134%

    Stock Price CAGR

    10 Years
    +11%
    5 Years
    +36%
    3 Years
    +44%
    1 Year
    +14%

    Return on Equity

    10 Years
    +7%
    5 Years
    +2%
    3 Years
    -3%
    Last Year
    +24%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderSept 2025Dec 2025Mar 2026Jun 2026Change
    Promoter46.64%46.65%46.65%46.65%0.00 pp
    FII20.73%19.20%20.35%20.89%+0.54 pp
    DII18.61%20.09%19.28%18.60%-0.68 pp
    Government0.04%0.04%0.04%0.04%0.00 pp
    Public13.97%14.02%13.70%13.81%+0.11 pp

    Filed with NSE for Jun 2026: promoters 46.65%, public 53.35% · XBRL filing

    Analysts & fund holdings

    83%
    83% recommend buy
    12 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E37.9 vs 46.4
    Sector P/B5.84
    Beta0.80

    Who holds the shares, quarter by quarter

    Mutual funds 16.76% (-0.04 pp)
    Mar 25
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    • Promoters46.6%
    • Foreign institutions20.9%
    • Mutual funds16.8%
    • Insurance1.0%
    • Other domestic institutions0.8%
    • Retail7.9%
    • Others5.9%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Mid Cap Fund5.08%3.07%+0.14 pp
    Invesco India Midcap Fund0.69%2.83%-0.98 pp
    Invesco India Contra Fund0.60%1.89%-0.22 pp
    Kotak Arbitrage Fund0.47%0.42%+0.12 pp
    Invesco India Large & Mid Cap Fund0.46%2.55%-0.76 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

    Corporate actions

    • dividend
      ₹2.50

      Dividend - Rs 2.50 Per Share

      31 Aug 2026
      ex-date
    • dividend
      ₹2.50

      Interim Dividend - Rs 2.50 Per Share

      3 Oct 2025
      ex-date
    • dividend
      ₹2.50

      Dividend - Rs 2.50 Per Share

      15 Sept 2025
      ex-date
    • dividend
      ₹2.50

      Dividend - Rs 2.50 Per Share

      13 Sept 2024
      ex-date
    • dividend
      ₹2.50

      Dividend - Rs 2.50 Per Share

      18 Sept 2023
      ex-date
    • dividend
      ₹2.50

      Annual General Meeting/Dividend - Rs 2.50 Per Share

      12 Sept 2022
      ex-date
    • dividend
      ₹2.50

      Annual General Meeting/Dividend - Rs 2.50 Per Share

      8 Sept 2021
      ex-date
    • dividend
      ₹2.50

      Annual General Meeting/Dividend - Rs 2.50 Per Share

      17 Sept 2020
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend - Rs 2 Per Share

      19 Sept 2019
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend Rs 2 Per Share

      19 Sept 2018
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend - Rs 2/- Per Share

      20 Sept 2017
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/ Dividend - Rs 2/- Per Share

      3 Aug 2016
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/ Dividend - Rs 2/- Per Share

      10 Sept 2015
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting / Dividend - Rs 2/- Per Share

      10 Jul 2014
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting / Dividend - Rs 2/- Per Share

      18 Jul 2013
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting / Dividend Rs 2 Per Share

      19 Jul 2012
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting And Dividend Re.0.40 Per Share

      28 Jul 2011
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting And Dividend Re.0.40 Per Share

      16 Sept 2010
      ex-date
    • other
      Not available — not reported in this filing

      Agm/Div-Re.0.40 Per Share

      10 Sept 2009
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      18 Sept 2008
      ex-date

    Bulk & block deals

    Large deals reported to NSE in this stock
    DateClientTypeQuantityPrice
    1 Sept 2026—Short sale8—

    Deals of more than 0.5% of shares (bulk), large single trades (block) and short sales, as NSE reports them.

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Glenmark expands Global Respiratory Innovation Footprint with RYALTRIS launch in Brazil

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Credit Rating

    Please find enclosed rating rationale issued by India Ratings and Research

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy ....

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Advertisement regarding the 48th Annual General Meeting ("AGM") to be held on Friday, September 11, 2026 at 2.00 p.m. through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")

    Company Update
    Letter To Shareholders Whose Email Address Are Not Registered Providing The Web Link Of Annual Report

    Letter to Shareholders whose email address are not registered providing the web link of Annual Report

    Others
    Business Responsibility and Sustainability Reporting (BRSR)

    Please find attached Business Responsibility and Sustainability Reporting for Financial Year 2025-26

    Others
    Reg. 34 (1) Annual Report.

    Please find attached Notice convening the 48th Annual General Meeting and the Integrated Annual Report including BRSR for the Financial Year 2025-26.

    AGM/EGMPrice-sensitive
    Notice Of The 48Th Annual General Meeting For The Financial Year 2025-26

    Please find attached Notice of 48th Annual General Meeting for the Financial Year 2025-26

    Company Update
    Settlement Agreement - Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015

    Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Intimation of Allotment of shares under the Employee Stock Option Plan 2016

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Analyst / Institutional Investor Meetings

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Advertisement regarding the 48th Annual General Meeting ("the AGM") to held through Video Conferencing ("VC")/ Other Audio-Visual Means ("OAVM")

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript of the Earnings Call

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Audio recording of Q1 FY 2026-27 Earnings Call held on August 03, 2026

    Filed with BSE (scrip 532296); the last 45 days. Documents open at bseindia.com.

    Documents

    Annual reports

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.